Myriad Genetics, Inc. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$210M↓-0.4%
2025-09-30$206M↓-3.6%$-27M↓-24.0%-11.3%
2025-06-30$213M↑+0.8%$-331M↓-800.5%-154.5%
2025-03-31$196M↓-3.1%$-100K↑+99.6%-14.8%
2024-12-31$211M↑+7.1%
2024-09-30$213M↑+11.2%$-22M↑+63.9%-9.4%
2024-06-30$212M↑+15.3%$-37M↑+68.4%-17.3%
2024-03-31$202M↑+11.6%$-26M↑+52.5%-13.8%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$210M
↓-0.4% -$800K YoY
Net Income
$104M
↑+3.9% +$4M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 67 quarters

margin trajectory tells the operating-leverage story
Gross Margin↓-1.7pts
70.0%
Operating Margin↓-2.0pts
-11.3%
Net Margin↓-3.0pts
-13.3%

Go deeper